EXAS vs NGNE · rev $2.76B vs $286.5M cap
EXACT Sciences Corporation (EXAS) versus Neurogene Inc (NGNE) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Neurogene Inc (NGNE) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported NGNE revenue for 2025-09-30 was $0. Net income was -$21.0M. NGNE currently screens at market cap $286.5M.
EXAS currently screens at market cap $20.03B. NGNE currently screens at market cap $286.5M.
Not investment advice. Open the EXAS and NGNE stock pages for the full models.
Not investment advice.